Summary
Relates to preserving access to affordable drugs; provides that an agreement resolving or settling, on a final or interim basis, a patent infringement claim, in connection with the sale of a pharmaceutical product, shall be presumed to have anticompetitive effects if a nonreference drug filer receives anything of value from another company asserting patent infringement and if the nonreference drug filer agrees to limit or forego research, development, manufacturing, marketing, or sales of the nonreference drug filer's product for any period of time.
How Congress Voted
Senate — Feb 24, 2026
63 votes
39(62%)
Yea
17(27%)
Nay
0(0%)
Present
7(11%)
Not voting
Senate — May 20, 2025
1 vote
1(100%)
Yea
0(0%)
Nay
0(0%)
Present
0(0%)
Not voting
Senate — Mar 4, 2025
2 votes
2(100%)
Yea
0(0%)
Nay
0(0%)
Present
0(0%)
Not voting
Related bills
Companion bill
Legislative Journey
- Introduced
- Committee
- Floor
- Passed Chamber 1
- Passed Chamber 2
- Signed
Jan 24, 2025
REFERRED TO HEALTH
SenateMar 4, 2025
REPORTED AND COMMITTED TO FINANCE
SenateApr 29, 2025
1ST REPORT CAL.755
SenateApr 30, 2025
2ND REPORT CAL.
SenateMay 1, 2025
ADVANCED TO THIRD READING
SenateMay 20, 2025
PASSED SENATE
SenateMay 20, 2025
DELIVERED TO ASSEMBLY
SenateMay 20, 2025
REFERRED TO HEALTH
HouseJan 7, 2026
DIED IN ASSEMBLY
HouseJan 7, 2026
RETURNED TO SENATE
HouseJan 7, 2026
REFERRED TO HEALTH
SenateFeb 9, 2026
1ST REPORT CAL.304
SenateFeb 10, 2026
2ND REPORT CAL.
SenateFeb 11, 2026
ADVANCED TO THIRD READING
SenateFeb 24, 2026
PASSED SENATE
SenateFeb 24, 2026
DELIVERED TO ASSEMBLY
SenateFeb 24, 2026
REFERRED TO HEALTH
House